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13.is not intended to be a comprehensive review, but to present
areas of emerging science for clinicians and scientists in
moving toward a better understanding of the long-term
management of patients with repaired TOF. Speciﬁcally,
the following topics are presented: 1) genetics; 2) the crucial
role of cardiac magnetic resonance (CMR) imaging; 3) recent
advances in echocardiography (ECHO); 4) arrhythmias
and sudden cardiac death (SCD); 5) surgical considerations
and catheter-based therapy; 6) exercise performance;
7) ventricular function and heart failure; and 8) timing of
and indications for pulmonary valve replacement (PVR).Genetics
The etiology of TOF is multifactorial. Up to 25% of patients
have chromosomal abnormalities, with trisomy 21 (Online
Mendelian Inheritance in Man [OMIM]1 190685) and1OMIM (Online Mendelian Inheritance in Man) is an online catalog of human genes
and genetic disorders developed by the National Center for Biotechnology Informa-
tion (NCBI) (http://www.omim.org/).
Abbreviations
and Acronyms
BNP = B-type natriuretic
peptide
CMR = cardiac magnetic
resonance
ECHO = echocardiography
EF = ejection fraction
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricular
NYHA = New York Heart
Association
PR = pulmonary
regurgitation
PVR = pulmonary valve
replacement
RV = right ventricular
SCD = sudden cardiac death
TAPSE = tricuspid annular
plane systolic excursion
TOF = tetralogy of Fallot
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215622q11.2 microdeletions (OMIM
188400, 192430, and 611867)
most frequent. Trisomies 18 and
13, as well as other less com-
mon chromosomal abnormalities,
have been reported. Chromosome
22q11.2 microdeletions occur
in approximately 20% of TOF
patients with pulmonary stenosis
and in 40% with pulmonary
atresia (1–4).DiGeorge syndrome
(DGS; OMIM188400), the most
severe type of 22q11.2 micro-
deletion, also includes palatal
abnormalities, dysmorphic facies,
learning disabilities, immune
deﬁciencies, and/or hypocalcemia
(5). A less severe 22q11.2 micro-
deletion in TOF, Shprintzen
(velocardiofacial) syndrome (VCFS;
OMIM 192430), does not include
the immune deﬁciencies or hypo-
calcemia of DiGeorge syndrome(5). Of the more than 40 commonly deleted 22q11.2
genes, only T-box 1 (TBX1) has been found in murine
models to be haploinsufﬁcient, with a phenotype convincingly
similar to that of the human syndrome. TBX1 missense and
truncating mutations have been identiﬁed in up to 30% of
patients with the nondeletion type and with the DGS/VCFS
phenotype (6,7).
Mutations of the jagged1gene (JAG1; chromosome20p12),
which cause Alagille syndrome, show clinical overlap with
22q11.2-deletion disorders and may cause isolated TOF (8).
Mutations of the NK2 homeobox 5 gene (NKX2.5; chromo-
some 5q35) have been reported in 4% of nonsyndromic
patients with TOF (9). Other knownTOF-associated genetic
variants include: zinc ﬁnger protein, multitype 2 (ZFPM2)
(10); growth differentiation factor 1 (GDF1) (11); GATA4
(12); cripto, Frl1, cryptic 1 (CFC1); forkhead box transcription
factor 1 (FOXH1) (13); teratocarcinoma-derived growth
factor 1 (TDGF1); nodal (NODAL) (14); and GATA6 (15).
Analysis of copy number variants has been used for identi-
fying 11 de novo copy number variants associated with TOF
(16). These regions included chromosomes 1q21.1, 3p25.1,
7p21.3, and 22q11.2. Arrington et al. (17) demonstrated that
haploinsufﬁciency of the lipoma preferred partner protein,
a member of the zyxin family of proteins, may cause TOF.
The risk for recurrence in a family is approximately 3%. If
a genetic basis for TOF is identiﬁed, family members with
congenital heart defects can be screened to determine the
risk for passing congenital heart defects on to future chil-
dren. Genetic data can also be used for risk stratiﬁcation in
patients regarding cardiac and noncardiac manifestations of
the disease.
Screening of patients with TOF could include ﬂuores-
cence in situ hybridization analysis of chromosome 22q11microdeletions or a chromosome microarray. If the result is
negative, consideration may be given to speciﬁc genetic-
mutation analyses.
Cardiac Magnetic Resonance
CMR is the gold standard quantitative assessment of
biventricular size and function, ﬂow measurements, and
myocardial viability (18,19). The goals of CMR in repaired
TOF include: 1) quantitative assessment of left ventricular
(LV) and right ventricular (RV) volumes, mass, stroke
volumes, and ejection fraction (EF); 2) quantiﬁcation of
pulmonary regurgitation (PR), tricuspid regurgitation,
cardiac output, and pulmonary-to-systemic ﬂow ratio; 3)
evaluation of regional wall motion abnormalities; 4) imaging
the anatomy of the RV outﬂow tract, pulmonary arteries,
aorta, and aortopulmonary collaterals; 5) assessment of
myocardial viability, including scar tissue in the ventricular
myocardium aside from sites of previous surgery; 6) evalu-
ation for residual intra- or extracardiac shunt; 7) evaluation
of the aortic valve for regurgitation and measurement of
aortic size; and 8) evaluation of the coronary arteries (20,21)
(Fig. 1). Despite the complex geometry and heavy trabecu-
lations of the RV, CMR measurements of ventricular size
and function in repaired TOF have shown good intra- and
interobserver reproducibility (22,23).
The indications for CMR in repaired TOF vary with age.
During the ﬁrst decade of life, CMR is indicated only when
imaging data necessary for clinical decision-making cannot be
obtained on ECHO. However, if there is concern regarding
the degree of RV volume load and dysfunction, CMR is
preferred over computed tomography or catheterization.
Beginning early in the second decade of life, CMR is indi-
cated as a routine test for the surveillance of PR, biventricular
size and function, dysfunction of other valves, and myocardial
viability assessment. Little information exists regarding the
optimal frequency of CMR following baseline examination.
In many patients, ventricular size and function remain stable
over many years. In others, the RV progressively dilates, and
its function declines over a short time period. Until new data
emerge to guide the frequency of CMR after baseline
examination, it may be reasonable to repeat the study every
3 years, or more frequently in patients with advanced disease.
CMR has emerged as a powerful tool for risk stratiﬁcation
in patients with repaired TOF. In a study of 793 patients
from 6 centers, Gatzoulis et al. (24) found that older age at
repair and QRS duration 180 ms were independent
predictors of SCD; this ﬁnding was later supported by
ﬁndings from Khairy et al. (25). However, those studies
lacked tools to measure RV size and function. More
recently, a study utilizing CMR for measuring ventricular
size and function found that severe RV dilation and RV and/
or LV dysfunction were independent predictors of heart
failure, sustained ventricular tachycardia, and SCD (26). In
a multicenter study of 871 patients with TOF, Valente et al.
(27) showed that although QRS duration 180 ms alone
Figure 1
Cardiac Magnetic Resonance Evaluation of a Large Right Ventricular Outﬂow Aneurysm in Patient With
Repaired Tetralogy of Fallot
Large aneurysm of the right ventricular outﬂow with an associated thrombus. (A) Cine SSFP image in an oblique coronal plane showing the right ventricular inﬂow (RV) and
outﬂow. Note the thin-walled aneurysm (An). (B) Oblique sagittal image of the aneurysm and the thrombus (arrow). (C) Imaging in the axial plane demonstrates that the
aneurysm ﬁlls the left superior hemithorax. The arrow in C is showing the same thrombus as in B.
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2157was a modest predictor of death or sustained ventricular
tachycardia (C ¼ 0.676; R2 ¼ 0.054), the addition of CMR-
measured RV mass-to-volume ratio and EF to a model of
prolonged QRS duration substantially improved outcome
prediction (C ¼ 0.833; R2 ¼ 0.23).
Echocardiography
Recent advances in ECHO (including 3-dimensional [3D]
ECHO) have improved the assessment of global and
regional RV performance. Techniques for measuring RV
volumes and RVEF by 3D ECHO have become available
over the past decade. These tools use databases of RV shapes
(generated from CMR images from many patients with
TOF) to best estimate RV size in individual patients,
although low resolution and an inability to perform real-time
volume acquisition remain limiting factors. Findings from
studies comparing the accuracy of measurements of RV
volumes and RVEF between 3D ECHO and CMR have
varied. In general, it has been suggested that 3D ECHO
underestimates RV volumes and may overestimate RVEF
(28), although the technique has not been applied to a large
population of patients with TOF.
Several methods of assessing global RV function in
patients with TOF have been studied. Tricuspid annular
peak systolic velocity (S0) (TAPSE) has been utilized as
a measure of RV systolic function and appears to correlate
with CMR-measured RVEF (29). TAPSE is a simple and
reproducible measure of RV systolic performance. RV ﬁbers
are primarily longitudinal (in contrast to those in the LV);
TAPSE determines the longitudinal motion of the RVusing 2-dimensional or M-mode ECHO for measuring the
distance that the tricuspid valve moves toward the apex in
systole (Fig. 2). TAPSE and RVEF have been strongly
correlated in adult cohorts without TOF (30). However,
a recent study suggests that the correlation between TAPSE
and RVEF in children with TOF is weak, perhaps due to
abnormal regional contraction, and thus, the overall value of
TAPSE in this population may be limited (31).
Myocardial isovolumic acceleration may be useful for
detecting early RV dysfunction. It is a relatively load-
independent measure and reﬂects RV contractility (32,33)
(Fig. 3). Reports have demonstrated that myocardial accel-
eration was lower in patients with severe PR than in those
with mild or moderate PR (32,33). Myocardial acceleration
also correlated inversely with QRS prolongation (32).
Patients with TOF have regional wall motion abnor-
malities such as diminished RV outﬂow tract contractility.
Therefore, global measures of RV performance may not
accurately reﬂect true RV function. Regional wall motion
measures, which utilize strain (regional deformation) and
strain rate (rate of regional deformation), may be advanta-
geous in patients with TOF because these methods avoid
geometric assumptions and allow for the measurement of
individual myocardial regions. In general, strain and strain
rate are globally impaired in post-operative TOF patients
(34–36). Reduced regional RV strain measures have also
been associated with severity of PR (35). A recent study
reported that global and RV free wall longitudinal peak
systolic strain continued to deteriorate in serial assessments
in adults after TOF repair, whereas RVEF remained the
same. These ﬁndings suggest that regional wall motion
Figure 2 Measurement of TAPSE
(A) Apical 4-chamber view in a patient with tetralogy of Fallot. The dotted line indi-
cates cursor placement at the tricuspid lateral annulus tomeasure tricuspid annular
plane systolic excursion (TAPSE), an indicator of ventricular contractile function.
(B) M-mode echocardiographic measurement of TAPSE, the longitudinal distance
(in centimeters) that the tricuspid annulus moves during systole (yellow line).
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LVEF was found to be abnormal in 21% of a large cohort of
adults with TOF (37). Although associated with RV systolic
dysfunction, LV systolic dysfunction was not associated with
severity of pulmonary regurgitation. LV and RV diastolic
dysfunction were found in 13.8% and 53.5%, respectively, of
adults with repaired TOF. Ventricular arrhythmias were
more prevalent in these patients (38).Arrhythmias and SCD
The most common arrhythmogenic mechanisms in TOF
involve surgical scars and natural conduction obstacles that
create narrow corridors capable of supporting macro–re-
entry. Atrial re-entrant tachycardia will develop duringextended follow-up in more than 30% of patients, and high-
grade ventricular arrhythmias will be seen in about 10% of
patients (39,40). The overall incidence of SCD is estimated
at 0.2%/yr of follow-up (24,41,42). Most SCD events
appear to be due to sustained ventricular tachycardia, with
a smaller portion related to rapidly-conducted atrial tachy-
cardia and, rarely, abrupt atrioventricular block (43).
Efforts to deﬁne an accurate scheme for the prediction
of ventricular tachycardia and SCD among patients with
TOF have been ongoing (24,44–51). Numerous clinical
variables have been identiﬁed (Table 1), providing reason-
ably strong negative predictive accuracy but only fair positive
predictive accuracy. The imperfections in risk stratiﬁcation
in patients with TOF have become more pronounced in the
modern era because therapy for individuals perceived to be at
high risk typically involves invasive measures, such as
implantable cardioverter-deﬁbrillator (ICD) placement,
surgery, or catheter ablation. The requirement of aggressive
therapies has resulted in a growing reliance on more
sophisticated testing with electrophysiologic studies and
CMR to improve risk stratiﬁcation (25,26,52,53). Many
patients deﬁned as high risk by the available criteria will not
experience an event during intermediate-term follow-up
(25,52,54), making the decision to accept the risks of
invasive therapy difﬁcult. Certain clinical variables have
emerged that help to describe the clinical proﬁle of TOF
patients at highest risk for ventricular tachycardia and SCD.
Multiple studies have veriﬁed that these patients are older
(>20 years of age); have undergone multiple cardiac opera-
tions (including initial palliative shunting); and have a
longer QRS duration and, importantly, evidence of compro-
mised LV systolic and/or diastolic function (55). The iden-
tiﬁcation of such factors has done much to improve the
surgical approach to TOF. Patients now undergo deﬁnitive
repair at a younger age (<2 years), with strong efforts made
to avoid ventriculotomy incisions and to preserve pulmonary
valve competence (48).
Potential sites for atrial macro–re-entry in patients with
TOF have been deﬁned. Two dominant circuits are recog-
nized: 1) rotation along the edge of the tricuspid valve, with
a narrow conduction corridor at the isthmus between the
inferior vena cava and the tricuspid valve ring (i.e., atrial
ﬂutter); and 2) rotation around a lateral atriotomy scar, with
a narrow conduction corridor between the lower edge of the
incision and the inferior vena cava (i.e., “incisional” tachy-
cardia) (56). Targeted ablation of these sites by catheter or
surgical means provides an effective approach to TOF
patients with frequent or highly-symptomatic recurrences
(57). Catheter and surgical mapping of monomorphic
ventricular tachycardia in patients with TOF has begun
to illuminate the multiple macro–re-entrant pathways that
can develop in the surgically-modiﬁed RV (58,59). The
most common circuits include: 1) the anterior RV surface
around a ventriculotomy incision (in patients with a
nontransannular patch); and 2) the septal surface to RV free
wall through the conal septum. The complex geometry of
Figure 3 Measurement of Myocardial Acceleration During Isovolumic Contraction on Tissue Doppler
(Left) The yellow outline shows the isovolumic contraction time period. (Right) Enhanced image shows how the myocardial isovolumic acceleration (IVA) is measured
(yellow line), with the velocity of myocardial motion measured against time (t).
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also allows for other circuits.
Drug therapy has largely been abandoned as the sole
treatment of TOF in patients with sustained ventricular
tachycardia and/or in those considered high risk. An ICD is
recommended for most patients, although catheter or
surgical ablation may be useful. The acute success rate for
ablation is now approximately 90%, but a 5% to 20%
recurrence rate limits widespread application of the tech-
nique (59–61). Ablation is often used in ICD recipients to
reduce the number of appropriate shocks.
It remains to be seen whether the risk for ventricular
tachycardia can be reduced by reverse remodeling in patients
with longstanding RV disease undergoing PVR and/or
RV scar resection. Preliminary data suggest that there is
potential for improved rhythm status if the intervention
is combined with mapping and ablation of ventricular
tachycardia circuits (47,62). However, surgical PVR alone
does not have a major impact on the risk for ventricularTable 1
Risk Factors for Ventricular Tachycardia and
Sudden Cardiac Death
Standard clinical variables
Older age at time of repair
Prior large palliative shunts
Older chronologic age
Recurrent syncope
Pulmonary regurgitation
Residual pulmonary stenosis
Severe RV enlargement
Depressed RV function
Depressed LV function
High-grade ventricular ectopy on Holter or exercise test
Prolonged QRS duration on electrocardiogram (>180 ms)
Advanced testing
Positive ventricular stimulation at electrophysiology study
Large RV size on CMR
Large pulmonary regurgitant fraction on CMR
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricular; RV ¼ right ventricular.tachycardia, at least when performed in TOF adults with
a longstanding hemodynamic burden. Reverse remodeling
and ventricular tachycardia reduction might be feasible if
surgery is performed earlier in the disease course (63).
ICDs are increasingly utilized in TOF. In a multicenter
study of 121 ICD implantations in TOF patients, Khairy
et al. (64) found appropriate discharges ranging from 7.7%
to 9.8%/year for primary and secondary prevention indica-
tions. Independent predictors of appropriate ICD discharge
included poor hemodynamics, such as increased LV end-
diastolic pressures and underlying arrhythmia (ventricular
tachycardia). In patients undergoing primary prevention, a
12-point risk score from 6 clinical variables (prior palliation,
inducible and spontaneous ventricular arrhythmias, QRS
duration, ventriculotomy, and LV end-diastolic pressure)
predicted appropriate ICD discharge. However, patients
had high risks for complications (30%) and inappropriate
discharges (approximately 6%/year). Witte et al. (65)
compared adult ICD recipients with TOF to those with
dilated cardiomyopathy. The patients with cardiomyopathy
were older (mean age 54SD12 vs. 25SD7 for TOF patients)
and were more likely to have had the ICD implanted for
secondary prevention. Interestingly, over the 2 years of
follow-up, the patients with TOF were less likely to have
received an appropriate discharge (5% vs. 23%) and were
more likely to have received inappropriate therapy (20% vs.
4%). These ﬁndings highlight the issues of ICD therapy in
this complex population.
Surgical Considerations
Increasing knowledge of morbidity associated with child-
hood repair of TOF mandates ongoing assessment of
current surgical approaches. Given that most major centers
now achieve hospital mortality rates of <2% (66), outcomes
analysis should focus on long-term preservation of RV and
patient functional status.
Neonatal versus non-neonatal repair. Neonatal primary
repair is promoted in many centers, although this practice is
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ture brain to the deleterious effects of cardiopulmonary
bypass (low ﬂow or deep hypothermic circulatory arrest)
balanced against the ongoing risks of hypoxemia (69).
Proponents emphasize the unpredictable nature of hyper-
cyanotic spells and the risk of conservative surveillance.
Opponents of neonatal repair note the anatomic constraints
of small-body intracardiac exploration, particularly the pres-
ervation of the crucial elements of RV function, including
tricuspid valve function, conduction system trauma, pulmo-
nary valve preservation, and avoidance of a ventriculotomy.
Neonatal palliation. Palliative shunting is still widely
practiced, with variable results (70). The technical difﬁculties
with shunt placement in newborns with small pulmonary
arteries and the challenges related to post-operative manage-
ment have resulted in many centers favoring complete repair
when operation is indicated in the ﬁrst 3 months of life.
Alternative strategies for palliation, including ductal and
RV outﬂow tract stent placement, have been described (71).
Surgical methodology. Although the conventional tech-
nique for complete surgical repair includes infundibulotomy
with or without an incision across the pulmonary valve
annulus, the transatrial/transpulmonary or infundibular
sparing method may offer improved intermediate-term RV
function and a lower risk for arrhythmia (72). Valve-sparing
techniques offer the theoretic advantage of long-term
pulmonary valve competence, but may be associated with
persistent RV hypertension (73). Late pulmonary valve
competence is lacking in monocusp repair techniques.
Intraoperative pulmonary balloon angioplasty with complete
transventricular repair may optimize pulmonary annular
growth but requires an RV incision and is of unproven long-
term beneﬁt (74). Techniques involving an RV incision are
affected by the presence of an anomalous anterior descend-
ing coronary artery; the transatrial/transpulmonary method
is not affected by this anomaly (75). Deﬁnitive longitudinal
outcomes data from comparisons of the various surgical
approaches are lacking (76,77).
Reoperation. PR is the most common indication for late
reoperation (78). The beneﬁts of earlier reoperation (in
adolescence or young adulthood) have been reported (77).
Options for pulmonary prosthesis include stented bio-
prosthesis (porcine or pericardial); expanded polytetra-
ﬂuoroethylene bivalved, homograft conduits; and other
conduits (stentless porcine, polyethylene terepthalate
porcine, and bovine jugular). The durability of stented
porcine versus pericardial is comparable and is preferred in
adults (79,80), particularly because it facilitates future per-
cutaneous pulmonary valve replacement. Polytetraﬂuoro-
ethylene bivalved prostheses are relatively new, and no late
data exist (81). Percutaneous valve replacement after this
procedure is not possible. Extracardiac conduits are avoided
when possible; their main role is in TOF with pulmonary
atresia. Relatively good durability of homograft conduit in
infants and small children make it a preferred conduit in this
age group (82). Homograft durability is better in anorthotopic position (i.e., inside native pulmonary artery or in
the position of the native pulmonary artery) compared with
an extracardiac position (right ventriculotomy to pulmonary
artery). Homografts and bovine jugular conduit durability in
infants and young children are similar, and given the limited
availability of homografts, the bovine conduit is widely used
(82). The durability of homografts in adulthood, however, is
inferior to those of standard stented and stentless bio-
prosthetic valves (83,84). Mechanical valves in the pulmo-
nary position are used rarely and are considered in patients
who require anticoagulation with warfarin for other reasons
or when there have been multiple prior operations (e.g., left-
sided mechanical prosthesis) (85).
Tricuspid regurgitation may be secondary to RV dilation
from PR or from a structural valve abnormality related to the
ventricular septal defect patch or chordal disruption at initial
repair. Tricuspid regurgitation can also be secondary to
permanent pacing or ICD leads. Tricuspid repair can be
accomplished with an eccentric, purse-string, or ringed
annuloplasty (86). Tricuspid replacement may be required if
prior repairs have failed or if there are major leaﬂet abnor-
malities. The risk of operation is greater with tricuspid
replacement (86).
Surgery for arrhythmia is performed most commonly for
atrial tachyarrhythmias (87). The most common are atrial
re-entry tachycardia, atrial ﬁbrillation, and ﬂutter. Atrial
ﬂutter is treated with cryoablation or radiofrequency ablation
of the right atrial isthmus. Paroxysmal atrial ﬁbrillation is
treated with right atrial maze, and continuous atrial ﬁbril-
lation is best treated with biatrial maze (88,89). The most
common arrhythmia following maze surgery is junctional or
slow sinus rhythm, which may require permanent pacing.
Prophylactic maze surgery at the time of reoperation for
other reasons (e.g., PVR) is controversial. Good results of
arrhythmia ablation have been reported with cut-and-sew,
radiofrequency, and cryoablation techniques. The overall
success of maze surgery may be determined more by
the location of lesions than by energy source (90). Ventric-
ular arrhythmias may be related to severe RV dilation,
ventriculotomy scar, or both. Treatment is aimed at
pre-operative mapping and percutaneous ablation. Intra-
operative ablation of a tachycardia focus can be performed at
the time of reoperation and is guided by mapping (pre-
operative or intraoperative).
Dilated ascending aorta is common in TOF, particularly
in adults. Limited natural history and treatment data are
available, and the timing of aortic intervention is contro-
versial. Dissection and aortic rupture in this patient group
are rare (91). Aortic valve competence is often preserved
despite aortic dilation. There are no guidelines for the
management of a dilated aorta in congenital heart disease
(78). In general, replacement of the ascending aorta is
indicated if it is 60 mm. The sinuses are left intact (i.e.,
supracoronary graft) if they are <40 mm. Aortic root
(composite graft) replacement is indicated if the sinuses
are 50 mm. Valve-sparing root replacement is preferred if
Figure 4 Streptococcus sanguinis Valve Endocarditis
Tetralogy of Fallot in a man age 20 years who underwent transcatheter implan-
tation of a Melody bovine jugular valve (Medtronic, Inc., Minneapolis, Minnesota)
with a stent system at the level of a bovine (pulmonary) valve conduit. The patient
was lost to follow-up after 7 weeks. He developed chills, fatigue, and dyspnea on
exertion. Echocardiography showed a large vegetation with severe pulmonary
stenosis and right ventricular dysfunction. On surgery, a large vegetation was
found attached to the implanted valve leaﬂet and to the stent wall.
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2161root replacement is necessary and the annulus is not
signiﬁcantly dilated. When the sinuses are between 40 and
50 mm, the technique of operation is individualized.
Catheter-Based Therapy
Patients with repaired TOF may have residual lesions
amenable to catheter intervention. Patients with residual
pulmonary artery stenosis are often amenable to catheter
balloon dilation, but most often require stent implantation
(92,93). Those with residual RV outﬂow tract obstruction
may be amenable to angioplasty or to RV outﬂow tract
stenting. Caution must be exercised to ensure that RV
outﬂow tract stenting does not cause coronary compression.
The original criteria for percutaneous Melody valve
implantation (Medtronic, Inc., Minneapolis, Minnesota) for
PR included RV–to–pulmonary artery conduits of 16 mm,
balloon sizing of the narrowest area to 14 and 20
mm, and moderate-to-severe PR or conduit stenosis
(gradient 35 mm Hg) (94).
The Sapien valve (Edwards Lifesciences Corporation,
Irvine, California) can be expanded to 26 mm and is
currently available only for patients participating in U.S.
Food and Drug Administration (FDA) trials. Because the
Melody valve has achieved approval by the FDA (Human-
itarian Device Exemption), it is being used more frequently
in unique situations in which a pre-existing conduit has not
been placed but there is some type of circumferential landing
zonedeither a pre-existing tissue pulmonary valve implant,
a previously implanted stent, or native narrowing of the RV
outﬂow tract. Initial reports following Melody implantation
noted potential stent fracture due to its position in the RV
outﬂow tract (94) within the contractile area of the RV and
often just under the sternum. Pre-stenting of the RV
outﬂow tract with 1 stent(s) to achieve a more stable,
ridged conduit prior to Melody placement has diminished
the occurrence of stent fracture (95). Endocarditis following
Melody valve placement has been reported (96–99) (Fig. 4).
Although there is considerable practice variation with anti-
biotic prophylaxis, the current guidelines recommend
prophylaxis for prosthetic valves (100).
Exercise Performance and Testing
There is evidence linking severe PR and RV dilation to
impaired exercise performance in patients with repaired
TOF. RV dysfunction leads to exercise intolerance and is
associated with SCD (24). Exercise testing not only is useful
in assessing overall clinical status and functional capacity, but
also may help to guide the timing of PVR because RV
dysfunction may manifest only during exercise and biven-
tricular electromechanical dyssynchrony may worsen. At
peak exercise, post-operative patients with TOF have lower
cardiac index and stroke volume (101). Peak oxygen
consumption during metabolic stress testing averages
approximately two-thirds of normal (102), and low peakoxygen consumption (36% predicted) has been shown to
correlate with mortality in adults with repaired TOF (103).
Exercise testing may help to identify TOF patients with
exertional arrhythmias.Ventricular Function and Heart Failure
B-type natriuretic peptide (BNP) has been shown to be
an important biomarker in patients with heart failure due to
LV dysfunction. Several studies have investigated the rela-
tionship between BNP and RV dysfunction. BNP levels in
TOF correlate with New York Heart Association (NYHA)
functional class. In contrast to levels in patients with LV
dysfunction, BNP elevations are mild. BNP has been re-
ported to correlate with ECHO and CMR estimates of RV
volume load, such as degree of PR and RV size. In a retro-
spective cohort study comparing plasma BNP levels during
long-term follow-up in 130 children and adults with
repaired TOF, Koch et al. (104) found that BNP was
positively correlated with the ECHO-derived ratio of RV
diastolic diameter to LV diastolic diameter as well as to
severity of tricuspid regurgitation and PR. Signiﬁcant
correlations of BNP and measurements of PR fraction with
CMR-derived RV volumes have also been reported (102).
Two studies have investigated the correlation between BNP
and exercise performance in TOF (BNP and exercise time
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increased plasma BNP levels in both groups. A greater
increase in BNP was noted in patients with TOF than in
controls (37.6  27.5 pg/ml vs. 11.3  4.5 pg/ml, p ¼
0.0001). Forced vital capacity (FVC%) (84.9  16.9 vs. 98.4
 18.2, p ¼ 0.01) and forced expiratory volume during the
ﬁrst second (FEV1%) (91.5  19.3 vs. 103.8  16.1, p ¼
0.02) were decreased, exercise duration (ED) (10.1  1.9
min vs. 11.4 1.7 min, p ¼ 0.02), maximum heart rate
(HRmax) (171.2  18.9/min vs. 186.4  13.9/min, p ¼
0.004), and maximum oxygen uptake (VO2max) (1.56  0.53
l/min vs. 2.1  0.6 l/min, p = 0.007) were lower in patients
with TOF (104,105).
With advances in transcatheter and surgical PVR, early
detection of RV dysfunction has become increasingly
important. RV function is affected by pre-load, afterload,
and contractility, as well as by synchrony of contraction and
ventricular interdependence (106). The deleterious effect of
chronic afterload due to RV outﬂow tract obstruction on RV
function is greater than that on the LV (107). Signiﬁcant
PR, RV outﬂow tract aneurysm, and akinesia can also
decrease cardiac output (108). RV volume overload may
negatively affect the function of both ventricles due to their
interdependence (107). Even patients with “well-repaired”
TOF may have residual hemodynamic abnormalities that
require serial surveillance (108).
There has been interest in evaluating the treatment
options for RV dysfunction in TOF (109). Babu-Narayan
et al. (110) reported the ﬁndings from a randomized trial
of ramipril for the treatment of RV dysfunction in adults
with repaired TOF. Their 6-month study in 64 patients
showed no differences in the primary and secondary
endpoints of change in RVEF, change in NYHA func-
tional class, exercise capacity, or BNP levels. Norozi et al.
(111) evaluated the effects of bisoprolol in the treatment
of patients with TOF and mild RV dysfunction. In their
randomized study, 33 adult patients with repaired TOF
were assigned to receive either bisoprolol or placebo for
6 months. No differences were seen in RVEF, NYHA
functional class, or exercise capacity; BNP was increased
signiﬁcantly only in the bisoprolol-treated group.
Resynchronization therapy has proved to be beneﬁcial in
patients with congenital heart defects. Among children
with TOF, isolated RV dysfunction, and right bundle
branch block, temporary RV pacing was associated with
improvements in cardiac index and RV contractility
indexes (112). Among adults with TOF and poor LV
function, RV pacing alone was associated with improved
RV contractility, but it had no apparent effect on the LV
(113); biventricular pacing was needed to increase
contractility of both ventricles. Endocardial electrical
mapping in adults with TOF has shown that the LV may
have delayed activation patterns masked by the overlying
right branch bundle block (114). Appropriate resynchro-
nization may depend on a patient’s age and underlying
electrical synchrony pattern.Timing of and Indications for PVR
There are several indicators useful for determining PVR in
the TOF patient with free PR and a dilated RV. Optimal
timing of PVR remains controversial because the unnatural
history of TOF with PR is not well deﬁned. Caution should
be exercised in the decision of early intervention because
there is a high incidence of conduit dysfunction, especially in
the young (115,116). Serial increases in RV volume and
worsening RVEF, along with exercise-testing measures and
symptoms attributable to RV volume overload, are factors
used for determining the timing of PVR (18,78). Other
factors to consider are RV hypertension, moderate to severe
tricuspid regurgitation, severe branch pulmonary arterial
stenosis, sustained tachyarrhythmia, and large RV outﬂow
tract aneurysm (30,78).
Ideally, PVR should occur prior to the development of
frank RV dysfunction, but this prediction is difﬁcult at
times. RV function may improve in the absence of irre-
versible myocardial changes. Therefore, PVR should be
considered in the face of signiﬁcant RV dilation (117).
Patients with chronic PR in whom LV dysfunction, heart
failure, or syncope develops may have adverse outcomes
(25,118). To date, there is no conclusive evidence that PVR
improves survival. Harrild et al. (62) reported no difference
in the composite outcome of ventricular tachycardia and
death between patients with post-operative TOF and those
who did not undergo PVR.Discussion
Much attention has been given to evaluation and manage-
ment of TOF to optimize disability-free survival. We have
summarized the latest information from experts for key
clinical issues to inform current practice, as follows:
1. From a genetic perspective, the etiology of TOF is
multifactorial, with a familial recurrence risk of 3%.
For nonsyndromic patients, ﬂuorescence in situ
hybridization for chromosome 22q11 microdeletion is
a reasonable starting point.
2. CMR is the gold-standard assessment tool on the
basis of its superior imaging of the RV outﬂow tract,
pulmonary arteries, aorta, and AP collaterals, and its
ability to quantify biventricular size and function, PR,
and myocardial viability (18,19).
3. ECHO is the primary tool for imaging in pediatric
patients. ECHO techniques that could provide reli-
able information for clinical decision making are
being developed. Regional RV strain and strain rate
may be useful for detecting early, subtle RV
dysfunction (36).
4. Atrial re-entrant tachycardia will develop during
extended follow-up in more than 30% of patients, and
high-grade ventricular arrhythmias will be seen in
about 10% of patients (39,40). The overall incidence
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(41,42). Risk stratiﬁcation, even with electrophysi-
ology testing and CMR, remains imperfect
(25,26,44–53). Drug therapy has largely been aban-
doned, and ICD placement, despite high risks for
complications and inappropriate discharges (64), is
often recommended for patients at higher risk.
5. Even today, deﬁnitive information about optimal
surgical strategies for primary repair to preserve RV
function, reduce arrhythmia, and optimize functio-
nal status are lacking (76,77). After primary repair,
reoperation for PR, tricuspid regurgitation, dilated
aorta, or arrhythmia is often performed, although
evidence is lacking about optimal timing and
technique.
6. Post-operative lesions are often amenable to trans-
catheter intervention and avoid the need for reopera-
tion. In selected cases, PR may be treated with
transcatheter valve insertion.
7. Ongoing surveillance of RV function is a crucial
component of clinical assessment and is a primary focus
of quantitative CMR and ECHO imaging. Serum
BNP has been correlated with ECHO and CMR
parameters of RV function and volume, as well as with
exercise performance. Current strategies to preserve
RV function are primarily related to the timing of
surgery or an interventional procedure. No known
medical therapies have been shown to be effective once
RV dysfunction occurs, although resynchronization
with biventricular pacing has been shown to improve
cardiac index and contractility (112,113).
8. In patients with signiﬁcant PR, optimal timing of
PVR remains uncertain.
Conclusions
Echocardiography and cardiac magnetic resonance imaging
techniques have, in many instances, replaced cardiac cathe-
terization as the primary diagnostic tool. They are particu-
larly useful in the assessment of pulmonary valve function,
ventricular volumes, and right ventricular performance,
which are key factors for risk stratiﬁcation. Genetic testing
may help identify syndromic patients with additional risk
factors. Surgical repair is associated with low mortality rates
(<2%), but many patients will require multiple surgeries,
with PR the most common indication for reoperation.
Catheter-based therapy, in selected patients, may prevent
additional surgeries. Optimal timing of PVR remains
uncertain, although newer and revised criteria are emerging.
Atrial re-entrant tachycardias are more common than
ventricular tachycardia but most SCD events are associated
with the latter.
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